API

Alpha Ketoanalogue (NA)

Drug classification

Kidnymax Tablet is a nutritional supplement; subclass: alpha ketoanalogue of essential amino acids.

Dosage form

Kidnymax Tablet is available as an oral tablet formulation.

API strength per dosage

Dose

Standard dosing for Alpha Ketoanalogue (Kidnymax Tablet) in adults with chronic kidney disease is typically based on body weight, often 1 tablet per 5 kg daily in divided doses with meals. Safety and efficacy in paediatric patients are not well established. Dose adjustment may be needed in severe hepatic impairment. Always use under specialist supervision.

Mechanism of action

Kidnymax Tablet contains alpha ketoanalogues of essential amino acids. These compounds are transaminated in the body to form essential amino acids, utilizing nitrogen from non-essential amino acids, thereby reducing nitrogenous waste production and uremic toxin accumulation in chronic kidney disease, while helping maintain protein nutrition without increasing renal nitrogen load.

Indications

Treatment of Chronic kidney disease

Side effects

Increased calcium level in blood

Pregnancy category

Safety of Alpha Ketoanalogue (NA) in pregnancy is not established; use only if potential benefits justify potential risks to the fetus. Consult a physician.

Precautions

Monitor renal function, serum electrolytes, calcium, phosphate, and nitrogen balance; assess for hypercalcemia; use cautiously in patients with hypercalcemia or hypersensitivity; ensure adequate caloric intake; adjust protein intake as advised; not for use in severe hepatic insufficiency; monitor for gastrointestinal disturbances.

Contraindications

Hypersensitivity to alpha ketoanalogues, hypercalcemia, disturbed amino acid metabolism, pregnancy, breastfeeding, severe hepatic insufficiency.